TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36465342
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT)
Study: 33930124
Drug: Vaginal micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily
Study: 32676977
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral administration)
Study: 34916722
Drug: Same-day PEG-ASC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same-day PEG-ASC regimen (5 mL sodium picosulfate in the evening and 1.5 L PEG-ASC on the day of colonoscopy)
Study: 34916722
Drug: Split-dose PEG-ASC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG-ASC regimen (1 L PEG-ASC before the day of colonoscopy and 1 L PEG-ASC on the day of colonoscopy)
Study: 34916722
Drug: Split-dose PEG-ASC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose PEG-ASC regimen
Study: 33469832
Drug: Vibegron 75
Normalized name: vibegron 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibegron 75 mg once daily
Study: 32090517
Drug: Liraglutide 3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 3.0 mg plus IBT
Study: 32645164
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (Pitavastatin)
Study: 33341937
Drug: Glyburide treatment
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide treatment in intermediate group
Study: 33341937
Drug: Glyburide treatment
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide treatment in wild-type genotype group
Study: 33341937
Drug: Glyburide dosage
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide dosage in variant genotype group
Study: 33341937
Drug: Glyburide dosage
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide dosage in wild-type genotype group
Study: 33341937
Drug: Glyburide dosage
Normalized name: Glyburide
DrugBank: Glyburide (DB01016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyburide dosage in intermediate group
Study: 32893098
Drug: Neurodynamics therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamics therapy
Study: 34039457
Drug: Complete level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complete level C (CC) - passive APR with an anti‐chemical suit
Study: 33239413
Drug: Topical PHMB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical PHMB 0.06%
Study: 36177673
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shock wave therapy (LiESWT) at 0.25 mJ/mm2 and 3 pulses/second for a total of 3000 pulses over 8 weeks
Study: 36177673
Drug: Low-intensity extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity extracorporeal shock wave therapy (LiESWT)
Study: 35074890
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (cilostazol with aspirin or clopidogrel) in the 15-28 days group
Study: 35074890
Drug: Dual therapy
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual therapy (cilostazol with aspirin or clopidogrel) in the 29-180 days group
Study: 35074890
Drug: Monotherapy (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (aspirin or clopidogrel) in the 8-14 days group
Study: 34580947
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of maternal risk factors, mean arterial pressure (MAP), serum placental growth factor (PlGF), and serum soluble fms-like tyrosine kinase-1 (sFLT-1) (triple test)
Study: 34980184
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine (0.75 mg/kg, max 75 mg)
Study: 39146562
Drug: Placebo lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lotion
Study: 34139047
Drug: MM -
Normalized name: CKMM - Creatine kinase MM isoenzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM - mechanical debridement + metronidazole-minocycline ointment
Study: 34353650
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and Haloperidol (5 mg midazolam and 5 mg haloperidol intramuscular injection)
Study: 32158186
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg on a 4-week cycle)
Study: 36163892
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg once-daily
Study: 36247079
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline 0.9% solution for nasopharyngeal wash
Study: 34152880
Drug: Topical Lawsonia
Normalized name: Lawsonia inermis flowering top extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Lawsonia inermis L. (Henna) hydrogel (H.gel) applied four times a day for 2 weeks
Study: 34966120
Drug: Neuromuscular Electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular Electrical Stimulation (NMES) treatment, 4 sessions over 2 weeks
Study: 35940873
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Low dose and Conventional dose)
Study: 34351205
Drug: Concurrent expert
Normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent expert testimony
Study: 32443036
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) with 2000 U lipase/kg/day in 4 doses plus hypercaloric enteral supplements
Study: 32443036
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received hypercaloric enteral supplements only
Study: 32251360
Drug: L-dopa/benserazide 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa/benserazide 100/25 mg
Study: 32319233
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of platinum-based chemotherapy and niraparib maintenance alone
Study: 32147084
Drug: Eurhythmy Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eurhythmy Therapy (EYT)
Study: 32989920
Drug: Filgotinib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib (200 mg once daily for 15 days)
Study: 33462851
Drug: Thompson sampling
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thompson sampling for treatment allocation
Study: 32612355
Drug: Protein Supplement
Normalized name: PROTEIN SUPPLEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein Supplement
Study: 32612355
Drug: WB‐EMS &
Approvals — FDA: no, EMA: no, PMDA: no
Description: WB‐EMS & Protein Supplement
Study: 36029208
Drug: Dexamethasone therapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone therapy for 19 days
Study: 32960329
Drug: DSM-TACE (drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM-TACE (drug-eluting beads transarterial chemoembolization)
Study: 33263237
Drug: Plate fixation
Normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plate fixation and placebo injection at the fracture line
Study: 35751892
Drug: Liraglutide (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (0.6 mg)
Study: 33399989
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg)
Study: 33819495
Drug: 3-mg granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-mg granisetron
Study: 33819495
Drug: 1-mg granisetron
Normalized name: granisetron 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-mg granisetron
Study: 33616815
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (Arm 3)
Study: 32356023
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg kg‐1)
Study: 36400089
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (0.5 ml intramuscularly once a year for up to 3 years)
Study: 32185143
Drug: DNA extraction
Normalized name: Toxoplasma gondii DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: DNA extraction with specific pre‐treatments
Study: 35999527
Drug: NEPA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA and DEX (12 mg) on day 1, no further DEX (DEX1)
Study: 35999527
Drug: NEPA and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEPA and DEX (12 mg) on day 1, oral DEX (4 mg daily) on days 2-3 (DEX3)
Study: 35999527
Drug: DEX (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEX (4 mg twice daily) on days 2-4 (DEX4; control)
Study: 33964430
Drug: Intravenous tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tranexamic acid (TXA) 1 g plus 100 mL saline
Study: 33964430
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group (100 mL saline)
Study: 35450161
Drug: Moderate walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate walking thrice weekly (MOD × 3/week)
Study: 35450161
Drug: Moderate walking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate walking once weekly (MOD × 1/week)
Study: 35450161
Drug: Vigorous walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vigorous walking once weekly (VIG × 1/week)
Study: 36030400
Drug: Double-dose quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose quadrivalent inactivated vaccine before hospital discharge
Study: 33848441
Drug: Vibrating Mesh
Normalized name: MIcroAir Vibrating Mesh Nebulizer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vibrating Mesh Nebulizer (VMN) with salbutamol (2.5 mg)
Study: 33848441
Drug: Jet Nebulizer
Normalized name: Pari LC Jet Nebulizer Plus RE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jet Nebulizer (JN) with salbutamol (2.5 mg)
Study: 36164681
Drug: Fluoroscopy-guided transforaminal
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided transforaminal epidural steroid injection (TFESI)
Study: 32273696
Drug: Ginseng capsules
Normalized name: Nature's Way Asian Ginseng Capsules
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng capsules (200 mg, twice per day)
Study: 37804858
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart
Study: 32674036
Drug: Patient-centred medication
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-centred medication self-management support programme conducted by trained nurses
Study: 32116248
Drug: Learning Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Learning Therapy (LT), a combination of cognitive training and stimulation.
Study: 35630024
Drug: Bevacizumab (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (7.5 mg/kg every three weeks up to 17 cycles) combined with carboplatin (AUC 6) and paclitaxel (175 mg/m2 for the first six cycles)
Study: 36846742
Drug: Self-guided lifestyle
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-guided lifestyle intervention (ACTIVATE) including 1 virtual group session, digital tools (wireless scale, self-monitoring app), access to self-paced content via a secure website, and 12 weekly texts to reinforce health risk messaging
Study: 33794181
Drug: Long-acting cabotegravir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting cabotegravir (400 mg) and rilpivirine (600 mg) administered as two 2 mL intramuscular injections every 4 weeks for at least 96 weeks.
Study: 33794181
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care regimen (daily oral dolutegravir 50 mg, abacavir 600 mg, and lamivudine 300 mg for 20 weeks followed by continuation).
Study: 35276572
Drug: Psychotherapy (acceptance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychotherapy (acceptance and commitment therapy)
Study: 32164435
Drug: Isoproterenol infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol infusion
Study: 34704709
Drug: Bupivacaine 0.25%
Normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.25% plus 50 µg fentanyl (1 mL)
Study: 36047623
Drug: Telehealth treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telehealth treatment
Study: 34732236
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) administered to intensive induction therapy on days 1, 4, and 7
Study: 34732236
Drug: Gemtuzumab ozogamicin
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Gemtuzumab ozogamicin (GO) administered once on day 1 (GO-1)
Study: 34732236
Drug: Glasdegib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glasdegib as adjunct to consolidation therapy and as single-agent maintenance therapy for six months
Study: 34732236
Drug: Placebo as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo as adjunct to consolidation therapy and as single-agent maintenance therapy for six months
Study: 32907619
Drug: Hydroxychloroquine combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine combined with low-dose prednisone and anticoagulation
Study: 36201773
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (weekly text messages inquiring about infant feeding method)
Study: 32398443
Drug: Pregabalin 75
Normalized name: pregabalin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 75 mg/d
Study: 39378042
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg once daily
Study: 35388606
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks)
Study: 35388606
Drug: Oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral isotretinoin (0.5 mg/kg once daily for 16 weeks) + SM peeling (20% salicylic and 10% mandelic acid every 4 weeks for 16 weeks)
Study: 34062484
Drug: Nintedanib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (200 mg b.i.d. p.o. until disease progression)
Study: 34062484
Drug: Ifosfamide (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ifosfamide (3 g/m2 i.v. days 1–3, every 21 days for ≤6 cycles)
Study: 36179790
Drug: 120-second MicroPulse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-second MicroPulse Transscleral Laser Therapy (Total Energy 93.9J, Fluence 131.0J/cm2)
Study: 36179790
Drug: 100-second MicroPulse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100-second MicroPulse Transscleral Laser Therapy (Total Energy 78.25J, Fluence 109.2J/cm2)
Study: 36179790
Drug: 120-second MicroPulse
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 120-second MicroPulse Transscleral Laser Therapy
Study: 32090434
Drug: Plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen activator inhibitor-1 (PAI-1) levels at 1st assessment (1992-1993)
Study: 32090434
Drug: Plasminogen activator
Normalized name: Plasminogen activator
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasminogen activator inhibitor-1 (PAI-1) levels at 2nd assessment (2005-2006)
Study: 32870153
Drug: 4-mg perampanel
Normalized name: perampanel 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg perampanel fine granules (FG)
Study: 32870153
Drug: 4-mg perampanel
Normalized name: perampanel 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-mg perampanel tablet
Study: 35532041
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy
Study: 37515459
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (control group)
Study: 35790010
Drug: Low-TBS dosage
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-TBS dosage (1.91–2.07 mg/kg)
Study: 35790010
Drug: High-TBS dosage
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-TBS dosage (4.27–4.88 mg/kg)
Study: 34081848
Drug: Olaparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib (1 year of oral treatment)
Study: 34081848
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 year of treatment)
Study: 37745479
Drug: Low-dose propofol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose propofol
Study: 35331498
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive use (COC, n=9)
Study: 35411611
Drug: Lixisenatide 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 5, 10, and 20 μg once daily for 6 weeks
Study: 36569174
Drug: Standard regulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard regulated treatment for chronic non-communicable diseases
Study: 34116330
Drug: Azithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (250 mg, BID, three days a week)
Study: 34116330
Drug: Prednisolone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (5 mg, BID)
Study: 35090540
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine e-aid Cognitive Behavioral Therapy for Insomnia (TCM-eCBT-I)
Study: 33990151
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (health education, psychological intervention, and training of the oral muscle group)
Study: 33111942
Drug: Low-dose NGF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose NGF (1 µg) injections
Study: 33111942
Drug: Control injections
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control injections of isotonic saline
Study: 32757634
Drug: Osmotic Release
Normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH)
Study: 36310089
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice with 380 mg of nitrate (BR)
Study: 37256193
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo injection
Study: 33197676
Drug: Cupping Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cupping Therapy (CT)
Study: 34928491
Drug: Intranasal ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal ketamine
Study: 36350082
Drug: Prune treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prune treatments (50 g and 100 g)
Study: 36350082
Drug: Prunes (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prunes (50 g and 100 g)
Study: 33475255
Drug: JNJ-64565111 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64565111 5.0 mg
Study: 33475255
Drug: JNJ-64565111 7.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64565111 7.4 mg
Study: 33475255
Drug: JNJ-64565111 10.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64565111 10.0 mg
Study: 35410294
Drug: Multimodal intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multimodal intervention care (MIC) including ibuprofen, omega‐3‐fatty acid, oral nutritional supplement, weekly physical, psychiatric assessment, nutritional counseling, and complementary and alternative medicine.
Study: 33468454
Drug: tDCS added
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tDCS added to a 2-week camp-based therapy
Study: 33468454
Drug: Camp-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camp-based therapy alone
Study: 32343308
Drug: 1 μg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/ml of sufentanil plus 2.5 μg/ml of DEX (Group D)
Study: 32343308
Drug: 1 μg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 μg/ml of sufentanil (Group S)
Study: 39248270
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule
Study: 33855207
Drug: Combined use
Normalized name: CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined use of metformin, SGLT2 inhibitor, GLP1 receptor agonist, and basal insulin (step-down approach)
Study: 37857620
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg ketamine
Study: 35107563
Drug: Isoproterenol 0.5
Normalized name: isoproterenol 0.5% inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol 0.5 μg
Study: 32557643
Drug: Therapeutic monoclonal
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic monoclonal antibodies (mAbs)
Study: 32557643
Drug: Single-dose pharmacokinetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose pharmacokinetic model
Study: 34759549
Drug: Caudal epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal epidural block with 0.75 mL.kg ‐1 of 0.25% bupivacaine and 1 mcg.kg ‐1 of dexmedetomidine
Study: 33570787
Drug: 8 mm
Normalized name: potassium 8 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mm implants + OSFE (Group 2)
Study: 33570787
Drug: 10 mm
Normalized name: potassium 10 MMOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mm implants + OSFE (Group 3)